The U.S. FDA approved Cablivi in combination with plasma exchange and immunosuppression for treating acquired thrombotic thrombocytopenic purpura (aTTP) in adults.
Sanofi wins European approval for rare blood-clotting disorder treatment
Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Acquisitions, Blood Clots, Blood Disorders, Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA), Fast Track Designation, FDA, FDA/Regulatory, NanobodiesThe French drugmaker Sanofi secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies.
One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.
Ghent, Belgium-based Ablynx NV announced the price of its U.S. initial public offering (IPO) at $17.50.
Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder.
